3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Skin Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Glioblastoma
2
Colorectal Neoplasms
2
Advanced Malignancies
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Recurrent Squamous Cell Carcinoma of Head
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Myelodysplastic Syndromes
1
Interventions
Ipilimumab
10
Nivolumab
9
Interleukin-2
5
Cyclophosphamide
5
pembrolizumab
3
incomplete Freund's adjuvant
3
fludarabine phosphate
3
Radiosurgery
3
Melphalan
3
ADI PEG20
3
sotrastaurin
2
fludarabine
2
Specimen Handling
2
Ranibizumab
2
Magnetic Resonance Spectroscopy
2
MART-1 Antigen
2
CTLA-4 Antigen
2
Biopsy
2
utomilumab
1
tocilizumab
1
siremadlin
1
sargramostim
1
ruxolitinib
1
relatlimab
1
pentetreotide
1
obinutuzumab
1
montanide ISA 51
1
lifileucel
1
gp100 Melanoma Antigen
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uveal Melanoma
×
cemiplimab
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled